Literature DB >> 2201326

Breast cancer screening in women over age 50. A critical appraisal.

P H Peeters1, A L Verbeek, G A Zielhuis, G P Vooijs, J H Hendriks, M Mravunac.   

Abstract

Breast cancer screening with mammography is strongly advocated by some and rejected by others. Discussions in the medical literature focus on the beneficial and unfavourable effects of breast cancer screening. Among the latter are the suggested excess mortality rate of screen-detected breast cancer patients, the high number of unnecessary biopsies, the possibility of overdiagnosis and subsequent unnecessary treatment, and the occurrence of interval breast cancer cases. It is concluded that screening can to a certain extent prevent women from dying of breast cancer but some negative effects are unavoidable. However, adequate training of the screening team can minimize the number of unnecessary biopsies and the occurrence of interval cancers. Research is needed to evaluate the natural course of so-called 'minimal' lesions, and to optimize screening tests. The search for new (imaging) techniques is needed to detect lobular cancers in dense breasts.

Entities:  

Mesh:

Year:  1990        PMID: 2201326

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  3 in total

1.  Long term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92.

Authors:  J D Otten; J A van Dijck; P G Peer; H Straatman; A L Verbeek; M Mravunac; J H Hendriks; R Holland
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

2.  Mammographic screening for breast cancer in family practice: A review of the literature.

Authors:  D Snadden
Journal:  Can Fam Physician       Date:  1992-08       Impact factor: 3.275

3.  Further evidence of benefits of a (non-randomised) breast cancer screening programme: the DOM project.

Authors:  H J Collette; F de Waard; J J Rombach; C Collette; N E Day
Journal:  J Epidemiol Community Health       Date:  1992-08       Impact factor: 3.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.